文献速递肝病消化道肿瘤与早癌

HCV肝硬化患者获得SVR后肝脏与非肝脏相关结局的发生率

Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
PubMed 文献 · J Hepatol · 2021-09-27

该纵向单中心研究纳入636例DAA治疗后获得SVR的HCV肝硬化患者,随访51个月,按治疗前病史分3组。5年累积肝相关事件发生率在无既往事件组为10.4%,有非HCC肝相关事件史组为32.0%,既往HCC组为71%。非肝相关事件发生率三组相近,全因死亡率在无既往事件组与一般人群相似。

要点

  • DAA治疗后获得SVR的HCV肝硬化患者仍面临肝相关和非肝相关事件风险。
  • 治疗前肝病病史强烈影响长期结局,既往HCC者5年肝相关事件发生率高达71%。
  • 无既往肝相关事件的Child-Pugh A患者全因死亡率与一般人群相似。

核心结论

  • HCV肝硬化患者DAA治疗后获得SVR仍面临肝相关和非肝相关事件及死亡风险,但发生率强烈受治疗前病史影响。

研究设计与样本

  • 纵向单中心研究,纳入636例DAA治疗后获得SVR的HCV肝硬化患者,中位年龄65岁,男性58%,Child-Pugh A占89%,随访51(8-68)个月。
  • 患者分为3组:A组(Child-Pugh A且无既往肝相关事件,n=480)、B组(Child-Pugh B或Child-Pugh A且有既往非HCC肝相关事件,n=89)、C组(既往HCC,n=67)。

主要发现

  • 5年估计累积肝相关事件发生率:A组10.4%,B组32.0%,C组71%(仅HCC)(p<0.0001)。
  • B组中HCC 19.7%、腹水8.6%、静脉曲张出血7.8%、肝性脑病2.5%;A组对应为HCC 7.7%、腹水1.4%、静脉曲张出血1.3%、肝性脑病0。
  • 5年估计非肝相关事件发生率:A组11.7%,B组17.9%,C组17.5%(p=0.32)。
  • 5年估计肝相关死亡与非肝相关死亡概率:A组0.5% vs 4.5%,B组16.2% vs 8.8%,C组12.1% vs 7.7%。
  • A组全因死亡率与按年龄、性别和日历年分层的一般人群预期死亡率相似,B组显著更高。

临床怎么用

  • 对DAA治疗后获得SVR的HCV肝硬化患者,应根据治疗前肝病病史分层管理,而非统一视为低风险。
  • 既往HCC患者治愈后肝相关事件风险仍高,需重点监测HCC复发。
  • 无既往肝相关事件的Child-Pugh A患者非肝相关事件和死亡占比相对突出,应关注肝外合并症管理。

局限性

  • 单中心研究,结果外推需谨慎。
  • 观察性设计,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: As the long-term benefits of a sustained virological response (SVR) in HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we assessed the incidence and predictors of liver-related events (LREs), non-liver-related events (NLREs) and mortality in DAA-treated patients with cirrhosis. METHODS: Consecutive patients with cirrhosis and SVR were enrolled in a longitudinal, single-center study, and divided into 3 cohorts: Cohort A (Child-Pugh A without a previous LRE), Cohort B (Child-Pugh B or Child-Pugh A with prior non-hepatocellular carcinoma [HCC] LREs), Cohort C (previous HCC). RESULTS: A total of 636 patients with cirrhosis (median 65 years-old, 58% males, 89% Child-Pugh A) were followed for 51 (8-68) months (Cohort A n = 480, Cohort B n = 89, Cohort C n = 67). The 5-year estimated cumulative incidences of LREs were 10.4% in Cohort A vs. 32.0% in Cohort B (HCC 7.7% vs. 19.7%; ascites 1.4% vs. 8.6%; variceal bleeding 1.3% vs. 7.8%; encephalopathy 0 vs. 2.5%) vs. 71% in Cohort C (HCC only) (p <0.0001). The corresponding figures for NLREs were 11.7% in Cohort A vs. 17.9% in Cohort B vs. 17.5% in Cohort C (p = 0.32). The 5-year estimated probabilities of liver-related vs. non-liver-related deaths were 0.5% vs. 4.5% in Cohort A, 16.2% vs. 8.8% in Cohort B and 12.1% vs. 7.7% in Cohort C. The all-cause mortality rate in Cohort A was similar to the rate expected for the general population stratified by age, sex and calendar year according to the Human Mortality Database, while it was significantly higher in Cohort B. CONCLUSIONS: Patients with cirrhosis and an SVR on DAAs face risks of liver-related and non-liver-related events and mortality; however, their incidence is strongly influenced by pre-DAA patient history. LAY SUMMARY: In this large single-center study enrolling patients with hepatitis C virus (HCV)-related cirrhosis cured by direct-acting antivirals, pre-treatment liver disease history strongly influenced long-term outcomes. In patients with HCV-related cirrhosis, hepatocellular carcinoma was the most frequent liver-related complication after viral cure. Due to improved long-term outcomes, patients with cirrhosis after HCV cure are exposed to a significant proportion of non-liver-related events.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. D'Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2021. PMID: 34592366. doi:10.1016/j.jhep.2021.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。